AVIR
NASDAQ
$4.78
Atea Pharmaceuticals Inc (AVIR)
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $8.67 (+81.57%)
Market Cap
$389M
Profit Margin
61%
Free Cash Flow Yield
-38.02%
Beta (5Y)
0.74
Price Chart
Valuation
Market Cap$389M
P/S1.55
P/B1.61
Profitability
Gross Profit (TTM)-$159M
EBITDA-$189M
Profit Margin61%
Operating Margin63.1%
EPS-$2.14
Financial Health
Free Cash Flow Yield-38.02%
Growth & Risk
Beta (5Y)0.74
Sharpe Ratio0.83